Feature Channels: Blood

Filters close
Newswise: Yale Study Reveals Clues to Help Treat Patients With COVID-19 Related Blood Clots
13-Dec-2021 3:55 PM EST
Yale Study Reveals Clues to Help Treat Patients With COVID-19 Related Blood Clots
Yale Cancer Center/Smilow Cancer Hospital

Blood clots or thromboembolic complications in patients with COVID-19 are associated with increased levels of various proteins that cause blood to clot, compared with people with blood clots unrelated to COVID-19, according to a small study by Yale Cancer Center researchers. These findings may offer insights into novel therapeutic strategies to treat patients with COVID-19 related blood clots. The findings were reported today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.

Newswise: Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
Released: 13-Dec-2021 3:55 PM EST
Yale Cancer Center Trial Identifies New Treatment Option for Certain Patients with T-Cell Lymphoma
Yale Cancer Center/Smilow Cancer Hospital

The final results from a national phase 2 study including researchers from Yale Cancer Center show the drug tipifarnib increased survival rates for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The findings are being presented today at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia.

10-Dec-2021 5:15 PM EST
Venetoclax combination therapies found effective against challenging subtypes of acute myeloid leukemia
University of Texas MD Anderson Cancer Center

Combination therapies including venetoclax and another therapy have displayed promising results against subtypes of acute myeloid leukemia (AML) that are particularly difficult to treat, including relapsed or refractory AML with a specific mutation, high-risk AML and treated secondary AML. Researchers from The University of Texas MD Anderson Cancer Center presented numerous studies involving venetoclax combination therapy for AML at the 2021 American Society of Hematology (ASH) Annual Meeting.

Released: 13-Dec-2021 2:40 PM EST
The American Society of Hematology recognizes Stephen Ansell, M.D. of Mayo Clinic with the 2021 Ernest Beutler Lecture and Prize
Mayo Clinic

The American Society of Hematology (ASH) has recognized Stephen Ansell, M.D., of Mayo Clinic with the highly distinguished Ernest Beutler Lecture and Prize as part of its Honorific Awards to recognize exemplary hematologists who have made significant contributions to the field and have been nominated by ASH members.

Newswise: Drug combination found to keep chronic lymphocytic leukemia in young patients in remission for several years
9-Dec-2021 10:00 AM EST
Drug combination found to keep chronic lymphocytic leukemia in young patients in remission for several years
Dana-Farber Cancer Institute

Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission. A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions of the disease.

Newswise: Examining the Development of T-cell Acute Lymphoblastic Leukemia
10-Dec-2021 12:05 PM EST
Examining the Development of T-cell Acute Lymphoblastic Leukemia
Rutgers Cancer Institute of New Jersey

Researchers from Rutgers Cancer Institute of New Jersey, the state’s only NCI-designated Comprehensive Cancer Center, examined the effects of SIRT1, an enzyme located primarily in the cell nucleus that contributes to cellular regulation on the transformation of T-cells.

Newswise: For patients with multiple myeloma, vaccination offers protection from COVID-19, but less than other cancer patients receive
11-Dec-2021 3:05 PM EST
For patients with multiple myeloma, vaccination offers protection from COVID-19, but less than other cancer patients receive
Dana-Farber Cancer Institute

For patients with the blood cancer multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection but to a far lower degree than the general population of cancer survivors, a new study by Dana-Farber Cancer Institute investigators shows.

Released: 11-Dec-2021 4:05 PM EST
Roswell Park Hematologists Present New Research on FLT3 Inhibitors, CART-19 at ASH Annual Meeting
Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center hematology experts in leukemia, lymphoma and other specialties will present new research at the 63rd annual meeting of the American Society of Hematology (ASH), which begins today in Atlanta, Georgia. The many research projects to be highlighted include breakthrough research on CAR T cell therapy, immunotherapy, leukemia, lymphoma and the management of genetic mutations in aggressive and rare blood cancers.

10-Dec-2021 5:20 PM EST
Mount Sinai Researchers Present Encouraging Clinical Trial Results on Novel Therapy for Bone Marrow Cancer
Mount Sinai Health System

Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual meeting in December.

Newswise: New study reveals elevated rates of blood cancer precursor condition in groups at high risk for multiple myeloma
11-Dec-2021 5:00 AM EST
New study reveals elevated rates of blood cancer precursor condition in groups at high risk for multiple myeloma
Dana-Farber Cancer Institute

The first results from the largest screening study yet conducted in the U.S. of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.

Newswise: Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner
Released: 11-Dec-2021 8:30 AM EST
Moffitt Study Shows Lymphoma Patients Can Benefit from Receiving CAR T Sooner
Moffitt Cancer Center

Chimeric antigen receptor T-cell therapy or CAR T is a breakthrough treatment for patients with certain types of blood cancers. The cellular therapy uses a patient’s own immune cells that are reengineered to better seek out and destroy cancer cells. The single infusion treatment is approved for patients who have relapsed after two or more types of therapy but results from the ZUMA-7 clinical trial show lymphoma patients can benefit from receiving the CAR T product axicabtagene ciloleucel (Yescarta) sooner.

9-Dec-2021 4:50 PM EST
Axi-cel CAR T cell therapy shows enhanced responses and continued benefit for high-risk lymphoma patients
University of Texas MD Anderson Cancer Center

Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting.

7-Dec-2021 4:20 PM EST
Potentially Serious Side Effect Seen in Patient after Immunotherapy
Mount Sinai Health System

Mount Sinai scientists have become the first to report a potentially serious side effect related to a new form of immunotherapy known as CAR-T cell therapy, which was recently approved for the treatment of multiple myeloma. Their findings were published as a case study in Nature Medicine in December.

Newswise: Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Released: 9-Dec-2021 11:40 AM EST
Exploring New Cancer Therapies that use a Patient’s Immune System to Fight Tumors
Rutgers Cancer Institute of New Jersey

Research underway at Rutgers Cancer Institute of New Jersey will contribute to the development of new cancer treatments that are based on the administration of cancer-fighting immune cells to patients.

Newswise: John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
Released: 9-Dec-2021 8:05 AM EST
John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual Conference
Hackensack Meridian Health

Researchers from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a part of the Georgetown Lombardi Comprehensive Cancer Center, will present updates on treatment advances in multiple myeloma, lymphoma, leukemia, and bone marrow transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually and live at the Georgia World Congress Center in Atlanta from December 11-14, 2021.

Released: 7-Dec-2021 12:05 PM EST
Targeted nanomedicine reduces vascular lesions, could help prevent stenosis
University of Chicago

A new targeted nanomedicine treatment developed at the University of Chicago has shown promise in reducing vascular lesions caused by atherosclerosis in a mouse model.

Released: 6-Dec-2021 1:30 PM EST
New marker for better assessing the severity of Covid-19
Ludwig-Maximilians-Universität München (Munich)

Biomedical scientists at LMU have found a new marker in the blood of Covid-19 patients. It furnishes insights into the course and development of the disease and could lead to better diagnoses.

Newswise: HPV-associated Head and Neck Cancer Blood Test Shows Promise as a Test to Replace Tissue Biopsy
1-Dec-2021 11:40 AM EST
HPV-associated Head and Neck Cancer Blood Test Shows Promise as a Test to Replace Tissue Biopsy
Massachusetts Eye and Ear

New research shows liquid biopsy for HPV-associated head and neck cancer is more than 98% accurate and obtained a diagnosis 26 days quicker on average than conventional tissue biopsy, in addition to costing 38% less. With HPV-associated head and neck cancer rates on the rise, there is a great need for more accurate, less-invasive, faster and less expensive diagnostic tests.

Released: 1-Dec-2021 11:55 AM EST
Seattle Children’s Presents Pediatric Cancer Immunotherapy Research Findings at American Society of Hematology Annual Meeting 2021
Seattle Children's Hospital

Seattle Children’s today announced five oral presentations at the American Society of Hematology (ASH) annual meeting, the world’s premier event in malignant and non-malignant hematology set to take place from Dec. 11-14.

Newswise: Blood Bubbles Reveal Oxygen Levels #ASA181
16-Nov-2021 2:45 PM EST
Blood Bubbles Reveal Oxygen Levels #ASA181
Acoustical Society of America (ASA)

Researchers have developed microbubbles to acoustically detect blood oxygen levels, since the microbubble shells are altered by structural hemoglobin changes in response to oxygen. The gas filling of the microbubbles causes them to oscillate and vibrate when ultrasound is applied, scattering energy and generating an acoustic response that can be detected by a clinical ultrasound scanner. Preliminary results show a strong correlation between oxygen concentration and the acoustic bubble response.

   
24-Nov-2021 12:45 PM EST
COVID-19: Measuring viral RNA to predict which patients will die
Universite de Montreal

A statistical model developed by Université de Montréal researchers uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19.

Released: 24-Nov-2021 2:35 PM EST
State Stem Cell Agency Awards $4M for Blood Cancer Immunotherapy at UC San Diego
UC San Diego Health

The California Institute for Regenerative Medicine (CIRM) approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

Newswise: Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome
Released: 22-Nov-2021 8:00 AM EST
Clonal Hematopoiesis in Donor May Improve Bone Marrow Transplant Outcome
Johns Hopkins Medicine

Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging. When looking for appropriate stem cell/bone marrow donors, clinicians tend to stay away from older donors with clonal hematopoiesis (CH) because of concerns about passing potentially premalignant stem cells to the recipient.

Newswise: Jeffrey L. Carson, MD, Recognized for Global Impact on Improving Transfusion Medicine
Released: 18-Nov-2021 11:45 AM EST
Jeffrey L. Carson, MD, Recognized for Global Impact on Improving Transfusion Medicine
Rutgers Robert Wood Johnson Medical School

Jeffrey L. Carson, MD, whose research has profoundly reshaped transfusion medicine is being honored by the American College of Physicians (ACP) with the John Phillips Memorial Award for Outstanding Work in Clinical Medicine for his career-long journey to improve health outcomes for patients.

15-Nov-2021 6:30 AM EST
CHOP-led Study Shows Novel Gene Therapy for Hemophilia A Leads to Sustained Expression of Clotting Factor and Reduced Bleeding Events
Children's Hospital of Philadelphia

A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and potentially life-threatening bleeding events, according to a new study led by researchers at Children’s Hospital of Philadelphia (CHOP). The results of the phase 1/2 trial, which were published today in the New England Journal of Medicine, are the first to demonstrate stable coagulation factor VIII in hemophilia A patients following gene therapy.

Released: 17-Nov-2021 11:00 AM EST
MD Anderson Research Highlights for November 17, 2021
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include discovering a new protein that regulates the DNA damage response, evaluating immunotherapy plus cryoablation to treat metastatic kidney cancer, identifying radiosensitizer targets to improve radiation therapy response, personalizing treatment intensity for acute myeloid leukemia, and identifying T cell features that play a role in response and resistance to cell therapy in leukemia.

Released: 16-Nov-2021 5:05 PM EST
Common Gene Variants Linked to Sepsis and COVID-19 Severity in African Americans
Perelman School of Medicine at the University of Pennsylvania

Two genetic risk variants that are carried by nearly 40 percent of Black individuals may exacerbate the severity of both sepsis and COVID-19, a team of researchers from the University of Pennsylvania’s Perelman School of Medicine have found.

Newswise: New Study in JNCCN Finds Disturbing Lack of Key Leukemia Medication
Released: 16-Nov-2021 8:35 AM EST
New Study in JNCCN Finds Disturbing Lack of Key Leukemia Medication
National Comprehensive Cancer Network® (NCCN®)

New research in JNCCN—Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial medication called all-trans retinoic acid (ATRA), initiated early in the treatment of acute promyelocytic leukemia (APL)—a form of acute myeloid leukemia (AML).

11-Nov-2021 1:55 PM EST
Milvexian an effective and safe oral pill for prevention of venous blood clots, says study
McMaster University

Researchers compared milvexian with enoxaparin for prevention of blood clots in 1,242 patients from18 countries undergoing knee replacement surgery who were enrolled between June 2019 and February 2021.They found that at a total daily dose of 100 mg or more, milvexian resulted in better clot protection but no increase in bleeding compared with enoxaparin, the control drug. Milvexian was evaluated in daily doses ranging from 25 to 400 mg; there was no increase in bleeding over this wide range of doses.

11-Nov-2021 3:15 PM EST
CHOP Study Finds Safest Treatment for Immunodeficiency Disorder is Not Cost Effective for U.S. Patients
Children's Hospital of Philadelphia

Patients with a rare immunodeficiency disorder who are treated with lifelong immunoglobulin replacement therapy (IRT) have a lower risk of premature death than patients treated with a hematopoietic stem cell transplant (HSCT), but they also have a reduced quality of life and must assume a substantial financial burden, according to a new study led by Children’s Hospital of Philadelphia (CHOP). Using a computational model to calculate the costs and benefits of IRT and HSCT for patients with agammaglobulinemia, the researchers concluded that the high cost of IRT in the U.S. undermines its cost-utility, particularly when compared to Canada and European countries, where the cost of IRT is nearly a third of what it is in the U.S.

Released: 11-Nov-2021 1:25 PM EST
New technique may lead to safer stem cell transplants
Washington University in St. Louis

Studying mice, researchers at Washington University School of Medicine in St. Louis have developed a method of stem cell transplantation that does not require radiation or chemotherapy. Instead, the strategy takes an immunotherapeutic approach, combining the targeted elimination of blood-forming stem cells in the bone marrow with immune-modulating drugs to prevent the immune system from rejecting the new donor stem cells.

Released: 10-Nov-2021 2:20 PM EST
Study: Recommended approach for preventing blood clots after stent placement may not be as beneficial as once thought
Beth Israel Deaconess Medical Center

A new study suggests that because of improvements in stent technology and changes in the types of patients receiving stents, the risks of DAPT may now outweigh the benefits for the average patient.

Released: 9-Nov-2021 9:55 AM EST
Researchers identify gene that contributes to secondary cancers
University of Chicago Medical Center

A new study by researchers at the University of Chicago Medicine Comprehensive Cancer Center sheds light on how a critical protein plays a significant role as a gatekeeper for keeping aggressive secondary malignancies developing after chemotherapy for solid tumors.

Released: 8-Nov-2021 2:25 PM EST
Study finds COVID-19 breakthrough cases can be severe for people with blood cancers
American Society of Hematology (ASH)

People with blood cancers are at a higher risk than healthy individuals for severe and life-threatening COVID-19 illness; furthermore, research suggests that they do not always achieve optimal protection from vaccination.

Released: 8-Nov-2021 8:50 AM EST
Study Examines Combined Effects of Medical Titration and Renal Denervation Treatment–Resistant Hypertension
Cardiovascular Research Foundation (CRF)

Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.

Newswise: Researchers have succeeded in identifying the proteins in the coronavirus that can damage blood vessels
Released: 3-Nov-2021 2:10 PM EDT
Researchers have succeeded in identifying the proteins in the coronavirus that can damage blood vessels
Tel Aviv University

Nearly two years since becoming a global pandemic that has killed millions of people, the mystery of which proteins in the SARS-CoV-2 virus are responsible for severe vascular damage that could even lead to heart attack or stroke has not yet been solved.

Released: 3-Nov-2021 9:00 AM EDT
What's it really like to give blood?
Michigan Medicine - University of Michigan

Tips and insights from a 5-gallon donor, aimed at people who have never given blood and those who stopped a while ago. A critical shortage of blood could jeopardize care for people with cancer, organ failure, traumatic injury and more.

Released: 1-Nov-2021 11:30 AM EDT
Comprehensive patient blood management program can reduce use of transfusions, improve patient outcomes
Mayo Clinic

A growing number of hospitals have implemented patient blood management programs to reduce unnecessary blood transfusions and costs. A study published in Mayo Clinic Proceedings finds that such a program can not only substantially reduce transfusion use, but also reduce length of hospital stays and in-hospital adverse outcomes.

Released: 29-Oct-2021 11:40 AM EDT
Making the case to improve outcomes for sickle cell disease
University of Alabama at Birmingham

UAB’s Julie Kanter, M.D., says statewide surveillance programs for sickle cell disease can help facilitate progress to improve outcomes.

Newswise: Vascular disease in COVID-19 is not caused by viral infection of blood vessels
Released: 27-Oct-2021 2:10 PM EDT
Vascular disease in COVID-19 is not caused by viral infection of blood vessels
University of Queensland

The SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots to COVID-19 patients, University of Queensland researchers have found.

Newswise: Albert Einstein Cancer Center Researcher Receives NCI Outstanding Investigator Award to Study Two Deadly Blood Diseases
Released: 27-Oct-2021 1:40 PM EDT
Albert Einstein Cancer Center Researcher Receives NCI Outstanding Investigator Award to Study Two Deadly Blood Diseases
Albert Einstein College of Medicine

Ulrich G. Steidl, M.D., Ph.D., co-director of the Blood Cancer Institute and associate director of basic science at the Albert Einstein Cancer Center (AECC), has received a prestigious Outstanding Investigator Award from the National Cancer Institute (NCI).

Newswise:Video Embedded covid-19-pandemic-shifted-patient-attitudes-about-colorectal-cancer-screening
VIDEO
20-Oct-2021 1:00 PM EDT
COVID-19 pandemic shifted patient attitudes about colorectal cancer screening
American College of Surgeons (ACS)

For people hesitant to come into the hospital or an outpatient center to get a colonoscopy, home-administered fecal occult blood tests (FOBT) may provide a useful workaround tool.

Newswise: TraumaChekTM: Next step in life-saving blood-assessment technology
Released: 20-Oct-2021 2:00 PM EDT
TraumaChekTM: Next step in life-saving blood-assessment technology
Case Western Reserve University

Scientists at Case Western Reserve University are leading the development of TraumaChekTM, a hand-held medical device to quickly assess a wounded soldier’s critical clotting issues and other blood conditions in the battlefield. The new sensor, if successful and adopted in the field, would represent the next generation of their successful ClotChip®, which emergency workers can use to measure how well a patient’s blood may clot.

Released: 20-Oct-2021 2:00 PM EDT
Penn Medicine Study Finds Red Blood Cells Play Much Larger Role in Immune System Through Discovery of DNA-Binding Capability
Perelman School of Medicine at the University of Pennsylvania

New research has revealed that red blood cells function as critical immune sensors by binding cell-free DNA, called nucleic acid, present in the body’s circulation during sepsis and COVID-19, and that this DNA-binding capability triggers their removal from circulation, driving inflammation and anemia during severe illness and playing a much larger role in the immune system than previously thought. Scientists have long known that red blood cells, which are essential in delivering oxygen throughout the body, also interacted with the immune system, but didn’t know whether they directly altered inflammation, until now. The study, led by researchers at the Perelman School of Medicine at the University of Pennsylvania, was published today in Science Translational Medicine.

Released: 20-Oct-2021 12:00 PM EDT
MD Anderson Research Highlights for October 20, 2021
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targeted therapy approaches for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), predicting survival following follicular lymphoma treatment, understanding how AML responds to checkpoint blockade therapy, identifying disparities in colorectal cancer screening, pregnancy outcomes following surgery for early-stage cervical cancer, and the discovery of a novel SHP2 targeted therapy.

Released: 20-Oct-2021 11:05 AM EDT
Treatment enhances anti-leukemia effect of bone marrow transplant, reduces recurrence, study finds
Michigan Medicine - University of Michigan

Researchers at the University of Michigan Health Rogel Cancer Center have identified a drug that, when given along with a bone marrow transplant, drops the risk of leukemia recurring by 20% among the high-risk patients.

Released: 14-Oct-2021 12:35 PM EDT
High Ferritin in Severe Covid-19 Pneumonia is Linked to Improved Outcomes After Steroid Treatment
Stony Brook University

Physicians from the Renaissance School of Medicine at Stony Brook University discovered that for patients with severe Covid-19 pneumonia who had higher ferritin in their blood and were treated with a corticosteroid, fewer intubations and deaths resulted. Their findings are reported in JAMA Network Open.

Released: 12-Oct-2021 4:25 PM EDT
Catching malaria evolution in the act
Texas Biomedical Research Institute

Ian Cheeseman, Ph.D., and his collaborators can now sequence the genomes of individual parasites found in the blood of infected patients -- even when the infection burden is very low, which can occur during asymptomatic infections. Gaining this incredibly detailed view is expected to help develop more effective treatments, vaccines or therapies.



close
1.55843